Adherence and protease inhibitor

NEW YORK, July 18 (Praxis Press) The complexity of antiretroviral regimens may be an obstacle to adherence among patients infected with the human immunodeficiency virus (HIV). Paterson and colleagues evaluated the importance of adherence to protease inhibitor therapy among HIV-infected patients (see paper). Good adherence was associated with decreased virologic failure, fewer days of hospitalization, and fewer opportunistic infections. An adherence level of 95% was identified as a critical level

July 21, 2000

NEW YORK, July 18 (Praxis Press) The complexity of antiretroviral regimens may be an obstacle to adherence among patients infected with the human immunodeficiency virus (HIV). Paterson and colleagues evaluated the importance of adherence to protease inhibitor therapy among HIV-infected patients (see paper). Good adherence was associated with decreased virologic failure, fewer days of hospitalization, and fewer opportunistic infections. An adherence level of 95% was identified as a critical level for optimal outcomes. Adherence is essential to successful protease inhibitor therapy, and underlying causes of poor adherence should be identified and addressed.

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.

AAAS